Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
psychopraxis. neuropraxis
Erschienen in:

08.11.2017 | Neurologie

Kognition und MS – ein unterschätztes Problem

verfasst von: Prof. Dr. phil. Dipl.-Psych. Iris-Katharina Penner

Erschienen in: psychopraxis. neuropraxis | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kognitive Teilleistungsstörungen treten bei Patienten mit Multipler Sklerose häufig auf. Um das kognitive Netzwerk so lange wie möglich zu erhalten, ist eine frühe Immuntherapie wichtig. Der kognitive Status sollte bei jedem neu diagnostizierten Patienten erhoben werden, um einen Verlauf über die Zeit nachvollziehen zu können.
Vorheriger Artikel Monoklonaler Antikörper hilft bei Migräne
Nächster Artikel Morbus Parkinson
Literatur
1.
Rao SM et al (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691CrossRefPubMed
2.
Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558CrossRefPubMed
3.
Khalil M et al (2011) Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 17:173–180CrossRefPubMed
4.
Feuillet L et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127CrossRefPubMed
5.
Lebrun C et al (2010) Cognitive function in radiologically isolated syndrome. Mult Scle 16:919–925CrossRef
6.
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed
7.
Amato MP, Ponziani G, Siracusa G, Sorbi S (2001) Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 58:1602–1606CrossRefPubMed
8.
9.
Ruet A et al (2013) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 260:776–784CrossRefPubMed
10.
Benedict RHB et al (2016) Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 22:1874–1882CrossRefPubMed
11.
Kobelt G et al (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. Epub ahead of print
12.
Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150CrossRefPubMed
13.
14.
15.
16.
Schoonheim MM et al (2015) Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology 84:776–783CrossRefPubMed
17.
Langdon DW et al (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891–898
18.
Smith A (1973) Symbol Digit Modalities Test Western Psychological Services
19.
Helmstaedter C, Lendt M, Lux S (2001) Beltz Test GmbH, Göttingen
20.
Benedict RH et al (1997) Psychological Assessment Resources Inc
21.
Fischer JS et al (2000) Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48:885–892CrossRefPubMed
22.
Penner IK et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 18:1466–1471CrossRefPubMedPubMedCentral
23.
Patti F et al (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 16:68–77CrossRefPubMed
24.
Patti F et al (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One 8:e74111CrossRefPubMedPubMedCentral
25.
Ziemssen T et al (2014) A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol 261:2101–2111CrossRefPubMedPubMedCentral
26.
Wilken J et al (2013) Changes in Fatigue and Cognition in Patients with Relapsing Forms of Multiple Sclerosis Treated with Natalizumab: The ENER-G Study. Int J MS Care 15:120–128CrossRefPubMedPubMedCentral
27.
Morrow SA et al (2010) Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 16:1385–1392CrossRefPubMed
28.
Forsberg L et al (2015) A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate. Poster presented at ECTRIMS 2015
29.
Benedict RHB et al (2017) Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler J. Epub ahead of print
30.
Benedict, RHB et al (2016) Improved cognitive outcomes in relapsing-remitting multiple sclerosis with daclizumab HYP in the phase 3 DECIDE study. Neurology 86(Suppl.):P3.090
31.
Mäurer M et al (2012) Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients. Mult Scler. Epub ahead of print
32.
Amato MP et al (2013) Treatment of cognitive impairment in multiple sclerosis: position paper. J Neurol 260:1452–1468CrossRefPubMed
33.
Sandroff BM, Hillman CH, Benedict RH, Motl RW (2015) Acute effects of walking, cycling, and yoga exercise on cognition in persons with relapsing-remitting multiple sclerosis without impaired cognitive processing speed. J Clin Exp Neuropsychol 37:209–2019CrossRefPubMed
34.
Sandroff BM, Hillman CH, Benedict RH, Motl RW (2016) Acute effects of varying intensities of treadmill walking exercise on inhibitory control in persons with multiple sclerosis: A pilot investigation. Physiol Behav 154:20–27CrossRefPubMed
35.
Vogt A et al (2009) Working memory training in patients with multiple sclerosis - comparison of two different training schedules. Restorative Neurology and Neuroscience 27:225–235PubMed
36.
Penner IK, Kappos L, Rausch M, Opwis K, Radü EW (2006) Therapy-induced plasticity of cognitive functions in MS patients: Insights from fMRI. Journal of Physiology Paris 99:455–462DOI: CrossRef
37.
Rosti-Otajärvi EM, Hämäläinen P (2014) Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Systematic Reviews 2:CD9131
Metadaten
Titel
Kognition und MS – ein unterschätztes Problem
verfasst von
Prof. Dr. phil. Dipl.-Psych. Iris-Katharina Penner
Publikationsdatum
08.11.2017
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 6/2017
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-017-0437-z

Weitere Artikel der Ausgabe 6/2017

Erfolgreiche Behandlung der Fluktuationen und Dyskinesien beim Parkinsonsyndrom

  • Open Access
  • Neurologie

Panorama

  • Panorama

Tagesklinik – mehr als eine Station ohne Betten

  • Psychiatrie

Alkoholabhängigkeit – eine chronische Krankheit

Psychiatrische Versorgung – wer betreut?

  • Psychiatrie

Morbus Parkinson

  • Neurologie